U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Oligoprogression

MedGen UID:
1690214
•Concept ID:
C5205436
•
Pathologic Function
Synonym: Oligoprogressive

Definition

Disease progression at a limited number of anatomic sites, in the context of stable disease at other anatomic sites. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVOligoprogression

Professional guidelines

PubMed

Management of oligoprogression in non-small cell lung cancer patients.
Tartarone A, Lerose R, Tartarone M
Med Oncol 2022 Feb 12;39(5):56. doi: 10.1007/s12032-022-01666-3. PMID: 35150371
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.
Donini M, Buti S, Massari F, Mollica V, Rizzo A, Montironi R, Bersanelli M, Santoni M
Expert Rev Anticancer Ther 2020 Jun;20(6):491-501. Epub 2020 Jun 1 doi: 10.1080/14737140.2020.1770601. PMID: 32479120
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P
Lancet Oncol 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PMID: 31908301

Recent clinical studies

Etiology

Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients.
Perng PS, Hsu HJ, Lee JS, Wang LC, Huang CY, Tien CH, Lai YH, Su PL, Hsu HH, Chen LY, Lee PH
World J Surg Oncol 2023 Nov 25;21(1):368. doi: 10.1186/s12957-023-03248-7. PMID: 38007448Free PMC Article
Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.
Mahmood U, Huynh MA, Killoran JH, Qian JM, Bent EH, Aizer AA, Mak RH, Mamon HJ, Balboni TA, Gunasti L, Ott PA, Awad MM, Schoenfeld JD
Int J Radiat Oncol Biol Phys 2022 Nov 15;114(4):666-675. Epub 2022 May 26 doi: 10.1016/j.ijrobp.2022.05.008. PMID: 35643252
Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.
Chang JY, Verma V
J Natl Compr Canc Netw 2022 May;20(5):531-539. doi: 10.6004/jnccn.2021.7117. PMID: 35545175
Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Sindhu KK, Leiter A, Moshier E, Lin JY, Carroll E, Brooks D, Shimol JB, Eisenberg E, Gallagher EJ, Stock RG, Galsky MD, Buckstein M
Cancer Treat Res Commun 2020;25:100216. Epub 2020 Oct 8 doi: 10.1016/j.ctarc.2020.100216. PMID: 33049542
The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Patel PH, Palma D, McDonald F, Tree AC
Clin Oncol (R Coll Radiol) 2019 Dec;31(12):824-833. Epub 2019 Jun 8 doi: 10.1016/j.clon.2019.05.015. PMID: 31182289Free PMC Article

Diagnosis

Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer.
Berghen C, Joniau S, Ost P, Poels K, Everaerts W, Decaestecker K, Haustermans K, Devos G, De Meerleer G
Eur Urol Oncol 2021 Apr;4(2):305-309. Epub 2019 Sep 23 doi: 10.1016/j.euo.2019.08.012. PMID: 31558422
Radiomics for liver tumours.
Dreher C, Linde P, Boda-Heggemann J, Baessler B
Strahlenther Onkol 2020 Oct;196(10):888-899. Epub 2020 Apr 15 doi: 10.1007/s00066-020-01615-x. PMID: 32296901Free PMC Article
Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer.
Deek MP, Tran PT
Cancer J 2020 Mar/Apr;26(2):137-143. doi: 10.1097/PPO.0000000000000432. PMID: 32205538Free PMC Article
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P
Lancet Oncol 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PMID: 31908301
Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma.
Diaz de Leon A, Pirasteh A, Costa DN, Kapur P, Hammers H, Brugarolas J, Pedrosa I
Radiographics 2019 Jul-Aug;39(4):998-1016. Epub 2019 Jun 14 doi: 10.1148/rg.2019180178. PMID: 31199711Free PMC Article

Therapy

Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients.
Perng PS, Hsu HJ, Lee JS, Wang LC, Huang CY, Tien CH, Lai YH, Su PL, Hsu HH, Chen LY, Lee PH
World J Surg Oncol 2023 Nov 25;21(1):368. doi: 10.1186/s12957-023-03248-7. PMID: 38007448Free PMC Article
Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.
Chang JY, Verma V
J Natl Compr Canc Netw 2022 May;20(5):531-539. doi: 10.6004/jnccn.2021.7117. PMID: 35545175
Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer.
Deek MP, Tran PT
Cancer J 2020 Mar/Apr;26(2):137-143. doi: 10.1097/PPO.0000000000000432. PMID: 32205538Free PMC Article
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P
Lancet Oncol 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PMID: 31908301
Reviewing RECIST in the Era of Prolonged and Targeted Therapy.
Morgan RL, Camidge DR
J Thorac Oncol 2018 Feb;13(2):154-164. Epub 2017 Nov 4 doi: 10.1016/j.jtho.2017.10.015. PMID: 29113950

Prognosis

Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.
Chang JY, Verma V
J Natl Compr Canc Netw 2022 May;20(5):531-539. doi: 10.6004/jnccn.2021.7117. PMID: 35545175
Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer.
Zhuo N, Liu C, Zhang Q, Li J, Zhang X, Gong J, Lu M, Peng Z, Zhou J, Wang X, Jiao X, Wang Y, Wang Y, Gao M, Shen L, Lu Z
JAMA Netw Open 2022 Mar 1;5(3):e224637. doi: 10.1001/jamanetworkopen.2022.4637. PMID: 35348710Free PMC Article
Radiogenomics in Interventional Oncology.
Moussa AM, Ziv E
Curr Oncol Rep 2021 Jan 2;23(1):9. doi: 10.1007/s11912-020-00994-9. PMID: 33387095
Radiomics for liver tumours.
Dreher C, Linde P, Boda-Heggemann J, Baessler B
Strahlenther Onkol 2020 Oct;196(10):888-899. Epub 2020 Apr 15 doi: 10.1007/s00066-020-01615-x. PMID: 32296901Free PMC Article
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P
Lancet Oncol 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. PMID: 31908301

Clinical prediction guides

Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.
Mahmood U, Huynh MA, Killoran JH, Qian JM, Bent EH, Aizer AA, Mak RH, Mamon HJ, Balboni TA, Gunasti L, Ott PA, Awad MM, Schoenfeld JD
Int J Radiat Oncol Biol Phys 2022 Nov 15;114(4):666-675. Epub 2022 May 26 doi: 10.1016/j.ijrobp.2022.05.008. PMID: 35643252
Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters.
Tan H, Cheung P, Louie AV, Myrehaug S, Niglas M, Atenafu EG, Chu W, Chung HT, Poon I, Sahgal A, Soliman H
Radiother Oncol 2021 Aug;161:159-165. Epub 2021 Jun 10 doi: 10.1016/j.radonc.2021.06.012. PMID: 34119585
Radiogenomics in Interventional Oncology.
Moussa AM, Ziv E
Curr Oncol Rep 2021 Jan 2;23(1):9. doi: 10.1007/s11912-020-00994-9. PMID: 33387095
Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Sindhu KK, Leiter A, Moshier E, Lin JY, Carroll E, Brooks D, Shimol JB, Eisenberg E, Gallagher EJ, Stock RG, Galsky MD, Buckstein M
Cancer Treat Res Commun 2020;25:100216. Epub 2020 Oct 8 doi: 10.1016/j.ctarc.2020.100216. PMID: 33049542
Radiomics for liver tumours.
Dreher C, Linde P, Boda-Heggemann J, Baessler B
Strahlenther Onkol 2020 Oct;196(10):888-899. Epub 2020 Apr 15 doi: 10.1007/s00066-020-01615-x. PMID: 32296901Free PMC Article

Recent systematic reviews

The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review.
Yan B, Ramadan S, Jerzak KJ, Louie AV, Donovan E
Curr Oncol 2023 Jul 21;30(7):6976-6985. doi: 10.3390/curroncol30070505. PMID: 37504365Free PMC Article
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AC, Feldman J, Gomez DR, Hesketh PJ, Jabbour SK, Jeter M, Josipovic M, Lievens Y, McDonald F, Perez BA, Ricardi U, Ruffini E, De Ruysscher D, Saeed H, Schneider BJ, Senan S, Widder J, Guckenberger M
Pract Radiat Oncol 2023 Sep-Oct;13(5):393-412. Epub 2023 Apr 25 doi: 10.1016/j.prro.2023.04.004. PMID: 37294262
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, Briganti A, Burger M, Choudhury A, Colecchia M, De Santis M, Fanti S, Fonteyne V, Gallucci M, Rivas JG, Huddart R, Junker K, Kroeze S, Loriot Y, Merseburger A, Montironi R, Necchi A, Oing C, Oldenburg J, Ost P, Pinkawa M, Ribal MJ, Rouprêt M, Thoeny H, Zilli T, Hoskin P
Eur Urol 2023 Oct;84(4):381-389. Epub 2023 May 20 doi: 10.1016/j.eururo.2023.05.005. PMID: 37217391
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials.
Kim H, Venkatesulu BP, McMillan MT, Verma V, Lin SH, Chang JY, Welsh JW
Int J Radiat Oncol Biol Phys 2022 Nov 15;114(4):676-683. Epub 2022 Aug 13 doi: 10.1016/j.ijrobp.2022.08.027. PMID: 35973624

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...